SCHEMBL3485526

SCHEMBL3485526

CCN(CC)c1ccc(C(F)(F)F)cc1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.44
MAPT P10636 3/20 0.44
LMNA P02545 2/20 0.44
ATM Q13315 1/20 0.44
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 3/20 0.42
PKM P14618 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CFTR P13569 1/20 0.41
S100B P04271 1/20 0.41
RAB9A P51151 1/20 0.41
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
GFER P55789 1/20 0.39
KMT2A Q03164 1/20 0.39
BACE1 P56817 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL171090 0.81 HRH4 (0.40) S100BHRH4NR1H2NR1H3DHFR
SCHEMBL2968966 0.79 GAA (0.50) L3MBTL1MAPTLMNAATMALDH1A1
SCHEMBL23549985 0.76 DHFR (0.39) MAPTLMNAS100BSLC6A4MAPK1
SCHEMBL23549967 0.76 CES2 (0.42) DHFRPDE2A
SCHEMBL8776727 0.75 ALDH1A1 (0.50) L3MBTL1MAPTATMALDH1A1KDM4E
SCHEMBL1263719 0.75 SLC6A4 (0.44) L3MBTL1MAPTLMNAATMALDH1A1
Hydrochloric Acid SCHEMBL10901293 0.73 ALDH1A1 (0.48) L3MBTL1MAPTATMALDH1A1KDM4E
Hydrochloric Acid SCHEMBL7811958 0.73 ALDH1A1 (0.48) L3MBTL1MAPTATMALDH1A1KDM4E
SCHEMBL2411170 0.73 TDP1 (0.48) L3MBTL1MAPTALDH1A1HSD17B10S100B
SCHEMBL14367955 0.73 ALDH1A1 (0.52) L3MBTL1MAPTLMNAATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2666481-B9 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient HAGIWARA MASATOSHI (JP) 2019-05-22 EP disclosed
EP-2666481-B9 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient HAGIWARA MASATOSHI (JP) 2019-05-22 EP disclosed
EP-2666481-B1 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient HAGIWARA MASATOSHI (JP) 2018-11-14 EP disclosed
EP-1712242-B1 METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT HAGIWARA MASATOSHI (JP) 2018-05-30 EP disclosed
EP-1712242-B1 METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT HAGIWARA MASATOSHI (JP) 2018-05-30 EP disclosed
US-8816089-B2 Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity Hagiwara, Masatoshi (JP) 2014-08-26 US disclosed
US-8816089-B2 Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity Hagiwara, Masatoshi (JP) 2014-08-26 US disclosed
US-8816089-B2 Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity Hagiwara, Masatoshi (JP) 2014-08-26 US disclosed
CN-101837125-B Method of regulating phosphorylation of PTH protein and antiviral agents comprising SR protein activity regulator as the active ingredient HAGIWARA MASATOSHI 2014-02-26 CN disclosed
EP-2666481-A2 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient HAGIWARA, Masatoshi (JP) 2013-11-27 EP disclosed
US-20100016359-A1 METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY MASATOSHI HAGIWARA 2010-01-21 US disclosed
US-20100016359-A1 METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY MASATOSHI HAGIWARA 2010-01-21 US disclosed
US-7569536-B2 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene Hagiwara, Masatoshi (JP) 2009-08-04 US disclosed
US-7569536-B2 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene Hagiwara, Masatoshi (JP) 2009-08-04 US disclosed
US-7569536-B2 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene Hagiwara, Masatoshi (JP) 2009-08-04 US disclosed
US-20070135367-A1 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene HAGIWARA, MASATOSHI (JP) 2007-06-14 US disclosed
US-20070135367-A1 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene HAGIWARA, MASATOSHI (JP) 2007-06-14 US disclosed
US-20070135367-A1 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene HAGIWARA, MASATOSHI (JP) 2007-06-14 US disclosed
CN-1921885-A Method for controlling phosphorylation of SR protein and antiviral agent comprising SR protein activity controller as active ingredient HAGIWARA MASATOSHI (JP) 2007-02-28 CN disclosed
EP-1712242-A1 METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT HAGIWARA, Masatoshi (JP) 2006-10-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135367-A1 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene SRPK1, SARS1, SRPK3 L3MBTL1 2338/4885MAPT 3497/4885LMNA 4232/4885
US-20100016359-A1 METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY SRPK1, SRPK3, SRPK2 L3MBTL1 3792/4885MAPT 3912/4885LMNA 3518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.